Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
LEIDEN, the Netherlands, April 20, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 12:50pm ET. The conference is being held at the InterContinental Boston Hotel in Boston, MA, USA.
The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcasts will be available for 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]
